|
|
|
|
Home | Search | Advance Search | Browse | Online Submission | Documentation & FAQ | Team | Contact us |
|
| PolysacDB ID | 2374 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-1 |
| Antibody Type Class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2375 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-2 |
| Antibody Type Class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2376 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-4 |
| Antibody Type Class | IgM |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 21-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2377 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-5 |
| Antibody Type Class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 22-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2378 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-8 |
| Antibody Type Class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 22-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2379 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-9 |
| Antibody Type Class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 23-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2380 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-10 |
| Antibody Type Class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 23-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2381 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-11 |
| Antibody Type Class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 23-04-2011 |
| References | 4008045 |
| PolysacDB ID | 2382 |
| Carbohydrate Name | Type 8 Capsular polysaccharide (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe Name | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | Type 5 capsular polysaccharide consists of following residues : -4)-β-D-ManpNAcA3Ac-(1-->4)-α-L-FucpNAc-(1-->3)-β-D-FucpNAc-(1- |
| BCSDB Structure | N/A |
| Proposed Function | N/A |
| Antigenic Nature | Formalinized cells |
| Carrier Name | Nil |
| Conjugate Method | Nil |
| Antibodies | Mab 18-12 |
| Antibody Type Class | IgG3 |
| Assay System | ELISA and Bacterial agglutination assays |
| Cross Reactivity | This Mab reacted with each of five type 8 S. aureus strains but not with any type 5 strains. It was also completely unreactive with S. aureus strains possessing capsular types 1, 2, 4, and 7, but reacted with type 6 strain |
| Proposed Epitope | N/A |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab will be used in various studies of S. aureus capsular polysaccharides. In particular, the use of these antibodies should facilitate the biochemical purification and further characterization of these polysaccharides. In addition, these reagents can be used to investigate the role of capsular polysaccharides in the invasiveness and virulence of encapsulated strains of S. aureus. Knowledge gained from these studies will be applicable to the development of a suitable vaccine. These antibodies will also be evaluated as diagnostic reagents for use in staphylococcal disease |
| Curator ID | AA + AS |
| Date of Curation | 24-04-2011 |
| References | 4008045 |
|
Bioinformatics Centre, Institute of Microbial Technology, Sec - 39A, Chandigarh, India - 160036 |